Long-acting somatostatin analogue therapy and protein metabolism in patients with jejunostomies.
OBJECTIVE
Previous studies have shown that secretory losses in patients with end jejunostomy syndrome (EJS) on home parenteral nutrition (HPN) can be suppressed by the somatostatin analogue, octreotide, thus facilitating fluid balance. However, the hormone also has antianabolic actions that may interfere with the use of infused amino acids.


METHODS
Amino acid metabolism, pancreatic enzyme synthesis and secretion, and mucosal protein turnover were measured by primed/continuous intravenous infusion of [1-14C] leucine tracer, duodenal aspiration, and endoscopic mucosal biopsy techniques during hormonal stimulation with pentagastrin and cholecystokinin 8.


RESULTS
In comparison with normal healthy controls, baseline measurements of amino acid metabolism were normal in patients with EJS/HPN, but pancreatic enzyme synthesis and secretion were elevated. Octreotide therapy improved fluid balance but suppressed gut hormone (insulin, gastrin, glucagon, peptide YY) levels in blood and the uptake of amino acids into pancreatic enzyme and mucosal proteins, increasing oxidative losses.


CONCLUSIONS
Octreotide improves fluid balance in patients who have undergone jejunostomy but reduces the use of amino acids for splanchnic protein synthesis. This may interfere with the physiological process of adaptation to intestinal resection.
O'Keefe
S J
SJ
Division of Gastroenterology and Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota.
Haymond
M W
MW
Bennet
W M
WM
Oswald
B
B
Nelson
D K
DK
Shorter
R G
RG
D000328:Adult; D000368:Aged; D000596:Amino Acids / Q000378:metabolism; D000681:Amylases / Q000378:metabolism; D003692:Delayed-Action Preparations; D005260:Female; D005744:Gastric Acid / Q000378:metabolism; D005768:Gastrointestinal Hormones / Q000097:blood; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects / Q000378:metabolism; D007582:Jejunostomy / Q000009:adverse effects*; D008049:Lipase / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000009:adverse effects*; D010179:Pancreas / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D016331:Parenteral Nutrition, Home; D011506:Proteins / Q000378:metabolism*; D012778:Short Bowel Syndrome / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D014357:Trypsin / Q000378:metabolism; D014882:Water-Electrolyte Balance / Q000187:drug effects
D000596:Amino Acids; D003692:Delayed-Action Preparations; D005768:Gastrointestinal Hormones; D011506:Proteins; D008049:Lipase; D000681:Amylases; D014357:Trypsin; D015282:Octreotide